Zotarolimus Background


The inherent advance inhibitory backdrop of abounding anti-cancer agents accomplish these drugs ideal candidates for the blockage of restenosis. However, these aforementioned backdrop are generally associated with cytotoxicity at doses which block corpuscle proliferation. Therefore, the different cytostatic attributes of the immunosuppressant rapamycin was the base for the development of zotarolimus by Johnson and Johnson.
Rapamycin was originally accustomed for the blockage of renal displace bounce in 1999. More recently, Abbott Laboratories developed a admixture from the aforementioned class, zotarolimus, as the aboriginal cytostatic abettor to be used alone for supply from drug-eluting stents to anticipate restenosis.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s